Sprint Bioscience AB (SPRINT) - Total Assets
Based on the latest financial reports, Sprint Bioscience AB (SPRINT) holds total assets worth Skr21.44 Million SEK (≈ $2.31 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Sprint Bioscience AB net assets for net asset value and shareholders' equity analysis.
Sprint Bioscience AB - Total Assets Trend (2011–2024)
This chart illustrates how Sprint Bioscience AB's total assets have evolved over time, based on quarterly financial data.
Sprint Bioscience AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Sprint Bioscience AB's total assets of Skr21.44 Million consist of 88.6% current assets and 11.4% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 59.6% |
| Accounts Receivable | Skr12.19 Million | 29.0% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr4.72 Million | 11.2% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Sprint Bioscience AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Sprint Bioscience AB market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sprint Bioscience AB's current assets represent 88.6% of total assets in 2024, an increase from 18.5% in 2011.
- Cash Position: Cash and equivalents constituted 59.6% of total assets in 2024, up from 2.6% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 29.0% of total assets.
Sprint Bioscience AB Competitors by Total Assets
Key competitors of Sprint Bioscience AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Sprint Bioscience AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.13 | 1.28 | 1.33 |
| Quick Ratio | 1.13 | 1.28 | 1.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr2.03 Million | Skr9.18 Million | Skr8.02 Million |
Sprint Bioscience AB - Advanced Valuation Insights
This section examines the relationship between Sprint Bioscience AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 38.45 |
| Latest Market Cap to Assets Ratio | 0.84 |
| Asset Growth Rate (YoY) | -32.6% |
| Total Assets | Skr42.05 Million |
| Market Capitalization | $35.31 Million USD |
Valuation Analysis
Near Book Valuation: The market values Sprint Bioscience AB's assets close to their book value (0.84x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Sprint Bioscience AB's assets decreased by 32.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sprint Bioscience AB (2011–2024)
The table below shows the annual total assets of Sprint Bioscience AB from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr42.05 Million ≈ $4.53 Million |
-32.58% |
| 2023-12-31 | Skr62.38 Million ≈ $6.71 Million |
+66.69% |
| 2022-12-31 | Skr37.42 Million ≈ $4.03 Million |
-52.71% |
| 2021-12-31 | Skr79.14 Million ≈ $8.52 Million |
+136.94% |
| 2020-12-31 | Skr33.40 Million ≈ $3.59 Million |
+73.56% |
| 2019-12-31 | Skr19.24 Million ≈ $2.07 Million |
-67.54% |
| 2018-12-31 | Skr59.29 Million ≈ $6.38 Million |
+67.08% |
| 2017-12-31 | Skr35.48 Million ≈ $3.82 Million |
-28.34% |
| 2016-12-31 | Skr49.52 Million ≈ $5.33 Million |
+61.66% |
| 2015-12-31 | Skr30.63 Million ≈ $3.30 Million |
+21.82% |
| 2014-12-31 | Skr25.15 Million ≈ $2.71 Million |
+236.55% |
| 2013-12-31 | Skr7.47 Million ≈ $804.11K |
+73.72% |
| 2012-12-31 | Skr4.30 Million ≈ $462.87K |
+55.02% |
| 2011-12-31 | Skr2.77 Million ≈ $298.60K |
-- |
About Sprint Bioscience AB
Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; TREX1, a drug candidate for the treatment of immuno-oncology, radiotherapy and chemotherapy in the treatment of cancer. It also develops PET… Read more